Enoxaparin utilization evaluation in inpatients with or at risk of thromboembolic disorders: A one-year, single-centered, retrospective Study
Publish place: Pharmaceutical and Biomedical Research، Vol: 2، Issue: 1
Publish Year: 1394
نوع سند: مقاله ژورنالی
زبان: English
View: 46
This Paper With 11 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_PBRE-2-1_007
تاریخ نمایه سازی: 10 دی 1402
Abstract:
The aim of this study was evaluation of enoxaparin utilization in hospitalized patients who had received enoxaparin either for prophylaxis or for treatment of thromboembolic disorders. A total of ۳۵۶ patients were included in this retrospective study and were analyzed for enoxaparin utilization in terms of prescription patterns, treatment strategy, dosing regimen, indications/contraindications, adverse drug reactions, bleeding events, drug-drug interactions and monitoring parameters. The inpatient records and charts were used to extract the relevant data. ۴۷.۸% of the patients were prescribed inappropriate doses of enoxaparin, and ۳۵.۷% were treated with enoxaparin for inappropriate duration. Lack of appropriate monitoring of platelet count, complete blood count (CBC), activated partial thromboplastin time (aPTT), serum potassium level and serum creatinine during enoxaparin therapy was also noted in nearly one third of the patients. Furthermore, dose adjustment was not performed for ۸۵% of the patients who had elevated serum creatinine. Co-administration of enoxaparin and anti-platelet drugs (aspirin and clopidogrel) or non-steroidal anti-inflammatory drugs were noted in ۷۲% of the patients. No cases of major bleeding occurred but hematuria was observed in ۱۶.۳% of the patients. High doses of enoxaparin (۱۲۰ mg/day), concurrent administration of antiplatelet drugs and increased age were found to be the main risk factors for bleeding. Overall, inappropriate utilization of enoxaparin in terms of prescription, dosing regimen, drug interaction and monitoring was observed in a large proportion of the patients which indicates the need for more careful consideration of the patients' conditions and the treatment guidelines before treatment with enoxaparin in the studied healthcare setting.
Keywords:
Authors
Shahram Ala
Phramaceutical Resaerch Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Gohar Eslami
Phramaceutical Resaerch Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Atieh sayftabar
Phramaceutical Resaerch Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :